Changes in insulin resistance and cardiovascular risk induced by PPARgamma activation have no impact on RBP4 plasma concentrations in nondiabetic patients.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme

Volumn 41, Issue 3, 2009, Pages 202-206

  Pfutzner A ^a   Schondorf T ^a   Hanefeld, M ^a   Lubben G ^a   Kann, P H ^a   Karagiannis, E ^a   Wilhelm, B ^a   Forst, T ^a  

^a Institute for Clinical Research and Development   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLASMA RETINOL BINDING PROTEIN; RBP4 PROTEIN, HUMAN; SIMVASTATIN;

ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; DIABETES MELLITUS; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INSULIN RESISTANCE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REFERENCE VALUE;

CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; DIABETES MELLITUS; GENE EXPRESSION REGULATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; PPAR GAMMA; REFERENCE VALUES; RETINOL-BINDING PROTEINS, PLASMA; SIMVASTATIN; THIAZOLIDINEDIONES;

EID: 65649138699     PISSN: None     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0028-1104592     Document Type: Article

References (0)